Open AccessImatinib mesylate in combination with pembrolizumab in patients with advanced KIT-mutant melanoma following progression on standard therapy
Author(s) -
Ikuko Hirai,
Keiji Tanese,
Keitaro Fukuda,
Takayuki Fusumae,
Yoshio Nakamura,
Yasunori Sato,
Masayuki Amagai,
Takeru Funakoshi
Publication year - 2021
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000027832
Subject(s) - medicine , imatinib mesylate , pembrolizumab , tolerability , melanoma , imatinib , oncology , mesylate , phases of clinical research , nilotinib , clinical trial , adverse effect , immunotherapy , cancer research , cancer , myeloid leukemia , organic chemistry , chemistry